Xilio Therapeutics (NASDAQ:XLO) Price Target Cut to $4.00 by Analysts at Raymond James

Xilio Therapeutics (NASDAQ:XLO) had its price target reduced by Raymond James from $6.00 to $4.00 in a research report released on Friday,Benzinga reports. They currently have an outperform rating on the stock.

Xilio Therapeutics Stock Performance

XLO traded down $0.05 during trading on Friday, reaching $0.99. The company’s stock had a trading volume of 206,853 shares, compared to its average volume of 539,527. Xilio Therapeutics has a 52-week low of $0.49 and a 52-week high of $1.93. The company’s fifty day moving average price is $0.88 and its 200-day moving average price is $0.95. The company has a market capitalization of $43.51 million, a price-to-earnings ratio of -0.47 and a beta of -0.24.

Xilio Therapeutics (NASDAQ:XLO) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.01). The firm had revenue of $2.36 million for the quarter, compared to the consensus estimate of $30.00 million. Equities analysts predict that Xilio Therapeutics will post -1.26 earnings per share for the current year.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Xilio Therapeutics stock. Renaissance Technologies LLC grew its stake in shares of Xilio Therapeutics, Inc. (NASDAQ:XLO) by 18.3% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 295,000 shares of the company’s stock after buying an additional 45,554 shares during the period. Renaissance Technologies LLC owned 0.80% of Xilio Therapeutics worth $280,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 54.29% of the company’s stock.

About Xilio Therapeutics

Xilio Therapeutics, Inc, a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company’s checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors.